Literature DB >> 24366637

Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies.

Eyal Robenshtok1, Azeez Farooki, Ravinder K Grewal, R Michael Tuttle.   

Abstract

Bone metastases from differentiated thyroid cancer are generally resistant to radioiodine (RAI) therapy and are associated with poor prognosis. However, in a recent study from our group we noted a small subgroup of patients with RAI-avid bone metastases who had no structural correlate on imaging studies, and had no skeletal complications during follow-up. The purpose of this study was to better define the natural history and outcome of these patients. In a retrospective review of medical records at Memorial Sloan-Kettering Cancer Center, 288 patients were identified with bone metastases from thyroid cancer between 1960 and 2011. Out of this group, 14 patients who had a RAI-avid bone metastasis without structural correlate on CT or MRI were included in the study. After a median follow-up period of 5 years (range 2-14 years) all patients were alive, none had evidence of structural bone metastases, and none had experienced skeletal-related events. The final disease status was: no evidence of disease in 6 patients (43 %), stable biochemical persistence in 2 patients (14 %), stable structural disease in 5 patients (36 %), and one patient with slowly progressive disease. To conclude, RAI-avid bone metastases with no structural correlate on high-resolution imaging studies often resolve following RAI treatment, do not cause skeletal-related complications, and do not have a major prognostic significance. Recognition of this unique type of bone metastases is important as it is not associated with the same poor prognosis and resistance to RAI therapy that is associated with structurally identifiable bone metastases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366637     DOI: 10.1007/s12020-013-0123-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  24 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

2.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

3.  Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases.

Authors:  J D Lin; M J Huang; J H Juang; T C Chao; B Y Huang; K W Chen; J Y Chen; K L Li; J F Chen; Y S Ho
Journal:  Thyroid       Date:  1999-12       Impact factor: 6.568

4.  Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer.

Authors:  Zhong-Ling Qiu; Hong-Jun Song; Yan-Hong Xu; Quan-Yong Luo
Journal:  J Clin Endocrinol Metab       Date:  2011-07-27       Impact factor: 5.958

5.  Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy?

Authors:  Georg Zettinig; Barbara J Fueger; Christian Passler; Klaus Kaserer; Christian Pirich; Robert Dudczak; Bruno Niederle
Journal:  Clin Endocrinol (Oxf)       Date:  2002-03       Impact factor: 3.478

6.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma.

Authors:  M Schlumberger; M Tubiana; F De Vathaire; C Hill; P Gardet; J P Travagli; P Fragu; J Lumbroso; B Caillou; C Parmentier
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

7.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables.

Authors:  J J Ruegemer; I D Hay; E J Bergstralh; J J Ryan; K P Offord; C A Gorman
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

8.  Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome.

Authors:  Elif Hindié; Paolo Zanotti-Fregonara; Isabelle Keller; Françoise Duron; Jean-Yves Devaux; Marie Calzada-Nocaudie; Emile Sarfati; Jean-Luc Moretti; Philippe Bouchard; Marie-Elisabeth Toubert
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

9.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine.

Authors:  F Pacini; F Cetani; P Miccoli; F Mancusi; C Ceccarelli; F Lippi; E Martino; A Pinchera
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

10.  False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer.

Authors:  Jong-Ryool Oh; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10
View more
  8 in total

1.  Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer.

Authors:  Domenico Albano; Maria Beatrice Panarotto; Rexhep Durmo; Carlo Rodella; Francesco Bertagna; Raffaele Giubbini
Journal:  Endocrine       Date:  2018-08-15       Impact factor: 3.633

2.  Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival.

Authors:  Arnaud Jannin; Livia Lamartina; Coralie Moutarde; Mehdi Djennaoui; George Lion; Benjamin Chevalier; Marie Christine Vantyghem; Frédéric Deschamps; Julien Hadoux; Eric Baudin; Martin Schlumberger; Sophie Leboulleux; Christine Do Cao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-12       Impact factor: 10.057

Review 3.  Treatment of distant metastases from follicular cell-derived thyroid cancer.

Authors:  Martin Schlumberger; Sophie Leboulleux
Journal:  F1000Prime Rep       Date:  2015-02-03

4.  Locoregional progression-free survival of bone metastases from differentiated thyroid cancer.

Authors:  Jiaxin Luo; Weili Yin; Qiuxia Lin; Juqing Wu; Pan Chen; Yuanna Ling; Jing Wang; Zhen Li; Liqin Pan; Yanying Chen; Wei Ouyang; Huijuan Feng
Journal:  Endocr Connect       Date:  2022-03-24       Impact factor: 3.335

Review 5.  Strategies for Radioiodine Treatment: What's New.

Authors:  Clotilde Sparano; Sophie Moog; Julien Hadoux; Corinne Dupuy; Abir Al Ghuzlan; Ingrid Breuskin; Joanne Guerlain; Dana Hartl; Eric Baudin; Livia Lamartina
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

6.  Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome.

Authors:  Renaud Ciappuccini; Natacha Heutte; Audrey Lasne-Cardon; Virginie Saguet-Rysanek; Camille Leroy; Véronique Le Hénaff; Dominique Vaur; Emmanuel Babin; Stéphane Bardet
Journal:  BMC Cancer       Date:  2020-08-14       Impact factor: 4.430

Review 7.  Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues.

Authors:  A Nervo; A Ragni; F Retta; M Gallo; A Piovesan; V Liberini; M Gatti; U Ricardi; D Deandreis; E Arvat
Journal:  J Endocrinol Invest       Date:  2020-08-03       Impact factor: 4.256

8.  RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.

Authors:  Désirée Deandreis; Aline Maillard; Slimane Zerdoud; Claire Bournaud; Lavinia Vija; Christophe Sajous; Marie Terroir; Laurence Leenhardt; Martin Schlumberger; Isabelle Borget; Sophie Leboulleux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-23       Impact factor: 9.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.